Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Pharmacol. 2010 Jun;10(3):246-53. doi: 10.1016/j.coph.2010.04.009. Epub 2010 May 6.

Beta-2 adrenergic agonists: focus on safety and benefits versus risks.

Author information

1
Wake Forest University Health Sciences, Center for Genomics and Personalized Medicine Research, Medical Center Boulevard, Winston-Salem, NC, United States. vortega@wfubmc.edu

Abstract

The use of beta(2)-adrenergic receptor agonists, or beta agonists, and their potential for an increased risk of asthma-related death were identified in the 1960's, and appears to have been related to the marketing of specific preparations of short-acting beta agonists (SABA) that are no longer in use today. Subsequent studies have reported a potential for life-threatening or fatal adverse events with the use of long-acting beta agonist (LABA) therapy, but this conclusion must be tempered by the suboptimal design of the studies which form the foundation for these conclusions. Multiple prospective clinical trials and meta-analyses have demonstrated that the combination of a LABA and an ICS confers proven clinical benefits which appear greater than the rare risk for serious or life-threatening adverse events, although all of these studies have inadequate power to be definitive.

PMID:
20452285
DOI:
10.1016/j.coph.2010.04.009
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center